EACS2023: 800 Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV S. Tordi , G.V. De Socio , D. Altobelli , A. Gidari , A. Zoffoli , D. Francisci University of Perugia, Department of Medicine and Surgery, Perugia, Italy General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The aim of the study is to evaluate the effectiveness, safety and tolerability of two-drug regimen (2-DR) with dolutegravir/lamivudine (DTG/3TC) versus a three-drug regimen (3-DR) with tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in a real-life cohort of HIV-1 virologically suppressed treatment-experienced (TE) people living with HIV (PLWH). Method: Retrospective, observational study analysing adult TE patients who started 2-DR or 3-DR between January 2018 and January 2023, according to the physician’s decision. All patients with a viral load (VL) <50 copies/mL at the time of switch and a follow-up of more than 6 months or interruption at any time were included. We excluded lost to follow-up patients. The primary endpoint was the maintenance of VL <50 copies/mL. Secondary endpoints included safety and tolerability. We also evaluate discontinuation for any reason, for virological failures, and for adverse events (AEs). A univariate statistical analysis was conducted by Mann Whitney test or χ2 test, as appropriate. Results: A total of 324 virologically suppressed individuals were included; their baseline characteristics are shown in Table 1. From these, 110 (34%) were on 2-DR and 214 (66%) were on 3-DR. The median follow-up was 19.6 months [IQR 14.2-26.4] in 2-DR and 27.5 months [IQR 15.3-32.6] in 3-DR (p=0.001). Most of PLWH remained on therapy in both groups (93.6% 2-DR versus 90.2% 3-DR). Overall, 99.1% achieved VL<50 copies/mL in 2-DR versus 97.2% in 3-DR (p=0.260) (difference: 1.9%; 95% CI 0.37 to 2.64), while virological failures occurred in 1.8% 2-DR versus 0.9% 3-DR. 4 patients (3.6%) were switched due to AEs on 2-DR group and 5 (2.3%) on 3-DR (p=0.142). The lipid profile was not influenced by switching to 2-DR or 3-DR ( Table 2) . Conclusions: Our study shows a similar good effectiveness and safety profile in virologically suppressed TE patients who switch to DTG/3TC or TAF/FTC/BIC. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 160 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=